- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Oesophageal carcinoma or gastroesophageal junction carcinoma
- Meeting Date: July 2022
- Public Summary Document (PSD) July 2022 PBAC Meeting - (PDF 1MB)
- Public Summary Document (PSD) July 2022 PBAC Meeting - (Word 662KB)
Nivolumab – July 2022
Nivolumab(oesophageal carcinoma or gastroesophageal junction carcinoma): Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo®
Last updated
11 November 2022